Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. We own and manage one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 200 development and commercial-stage assets. We fund high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Our royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. We also license our proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across our global partner network.